Drug Profile


Alternative Names: SD-101 - Scioderm; Zorblisa

Latest Information Update: 02 Jun 2017

Price : $50

At a glance

  • Originator Scioderm
  • Class Anti-inflammatories; Antiacnes; Antipsoriatics; Hydantoins; Imidazolidines; Keratolytics; Small molecules; Urea compounds
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Epidermolysis bullosa
  • No development reported Diabetic foot ulcer; Psoriasis

Most Recent Events

  • 31 May 2017 Allantoin receives Rare Pediatric Disease designation from the US FDA for Epidermolysis bullosa
  • 03 Apr 2017 Scioderm completes enrolment in the ESSENCE phase III trial for Epidermolysis Bullosa in USA, Australia, Spain, Austria, the Netherlands, France, Lithuania, Germany, Poland, the UK and Italy
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic-foot-ulcer in USA (Topical, Cream)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top